Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP128568.RAcQEvg_aY9bn01i-cgvUlwZEkAbaBCEnpJdN7OhGnzqA130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP128568.RAcQEvg_aY9bn01i-cgvUlwZEkAbaBCEnpJdN7OhGnzqA130_provenance.
• NP128569.RAcf5Tjg3_XsZr5nMRvz287z4T08KyMYkOSqM5vJnjRdg130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP128569.RAcf5Tjg3_XsZr5nMRvz287z4T08KyMYkOSqM5vJnjRdg130_provenance.
• NP128571.RAZLSVfi8V21keS2VL2twD2Y794mgp-Ogn6ic1Yrn1r8g130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP128571.RAZLSVfi8V21keS2VL2twD2Y794mgp-Ogn6ic1Yrn1r8g130_provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP132894.RAkzFeSdZpo5czPHLDsCuZhmiASspDyPGS-wp47ajdWJs130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP132894.RAkzFeSdZpo5czPHLDsCuZhmiASspDyPGS-wp47ajdWJs130_provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP185025.RATdugodV1vIU2pX4IbGJP1L8WPFuqd6Zk-h271zjJnEc130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185025.RATdugodV1vIU2pX4IbGJP1L8WPFuqd6Zk-h271zjJnEc130_provenance.
• NP185026.RAXJgg-lIyGOtpp0DNRME5ZfJZNzgzoIZJLxXB5nunJ6M130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185026.RAXJgg-lIyGOtpp0DNRME5ZfJZNzgzoIZJLxXB5nunJ6M130_provenance.
• NP185027.RAYu8v3MIrlT6NrO-ZQ_n_ePmUoatK4FSuMllXKBj9msY130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185027.RAYu8v3MIrlT6NrO-ZQ_n_ePmUoatK4FSuMllXKBj9msY130_provenance.
• NP185030.RARmfsThfgGcihqnmUmjxY0XPXD_S1utfo2-zXXZLNUrg130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185030.RARmfsThfgGcihqnmUmjxY0XPXD_S1utfo2-zXXZLNUrg130_provenance.
• NP185037.RAfkxmZ35ELSMggJszEJZZt4gWU0zOcIoUp2CCYXMo_Jg130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185037.RAfkxmZ35ELSMggJszEJZZt4gWU0zOcIoUp2CCYXMo_Jg130_provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP96277.RAvhNwJrfhhlATqgh85OmVLoqDpKRYxkmDMQyXp7MBS_I130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP96277.RAvhNwJrfhhlATqgh85OmVLoqDpKRYxkmDMQyXp7MBS_I130_provenance.
• NP128570.RAqCEEjQ3gQRITPwhONOio9xZHU2yZYtip4ulDzvn4S78130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP128570.RAqCEEjQ3gQRITPwhONOio9xZHU2yZYtip4ulDzvn4S78130_provenance.
• NP149814.RAiAceG46QPF_WgGXI9t_ctmmzbNajtotO3WjtdqImNgo130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP149814.RAiAceG46QPF_WgGXI9t_ctmmzbNajtotO3WjtdqImNgo130_provenance.
• NP149817.RAlLCXg4Lo_obUEAzWMfJkPBpq8tE0_lSHcNFHo_L6aFI130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP149817.RAlLCXg4Lo_obUEAzWMfJkPBpq8tE0_lSHcNFHo_L6aFI130_provenance.
• NP185029.RAAVcIB1TmWoJ942yAbysF_PbJhYrfVR4z9IR1u8zqbj0130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185029.RAAVcIB1TmWoJ942yAbysF_PbJhYrfVR4z9IR1u8zqbj0130_provenance.
• NP185031.RACemtQT5scujSo83iTHUtLqgNIlK9olnM9y6Kd3zJIHU130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185031.RACemtQT5scujSo83iTHUtLqgNIlK9olnM9y6Kd3zJIHU130_provenance.
• NP185038.RAAFs6AvpjI_ng1zX_dSTc9FYsWU5j00NVSw3gnJUM8uA130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185038.RAAFs6AvpjI_ng1zX_dSTc9FYsWU5j00NVSw3gnJUM8uA130_provenance.
• NP185040.RAqNCuF7S55R2qlme1an2iLA3Q9Uoq2nPIGX4G19kdWxk130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185040.RAqNCuF7S55R2qlme1an2iLA3Q9Uoq2nPIGX4G19kdWxk130_provenance.
• NP185041.RAtw6RkTSZM-vM9SvGIihldSJ-pYIOQCnLwvZX5d84sms130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185041.RAtw6RkTSZM-vM9SvGIihldSJ-pYIOQCnLwvZX5d84sms130_provenance.
• NP185042.RAgGjm8oxUPxI69yBT2_bdYafs8y20ptCEs3rYHNJlcDI130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185042.RAgGjm8oxUPxI69yBT2_bdYafs8y20ptCEs3rYHNJlcDI130_provenance.
• NP128567.RAwlBfCAPABqTlbWHWibJ-vxUBlkT6wNxe6LSR9fbhHnI130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP128567.RAwlBfCAPABqTlbWHWibJ-vxUBlkT6wNxe6LSR9fbhHnI130_provenance.
• NP132895.RAzJuyyoLFgc5azXUckSVPW1T57SfeaYVTEim4D9TECvY130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP132895.RAzJuyyoLFgc5azXUckSVPW1T57SfeaYVTEim4D9TECvY130_provenance.
• NP132897.RAx3T57JIIF_DqBBj1UnKxWIEEocZPNBlhwd9dasE4H3E130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP132897.RAx3T57JIIF_DqBBj1UnKxWIEEocZPNBlhwd9dasE4H3E130_provenance.
• NP132896.RAGfrhDH3tI2rB--h2nhul3Cx0VrKMhLJMbpt_NKEAlG0130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP132896.RAGfrhDH3tI2rB--h2nhul3Cx0VrKMhLJMbpt_NKEAlG0130_provenance.
• NP149815.RAF-_pOIUhgm_jKjDaknO_gvCSrf5oTy2tmoWpkveZTHI130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP149815.RAF-_pOIUhgm_jKjDaknO_gvCSrf5oTy2tmoWpkveZTHI130_provenance.
• NP149816.RAFaAvWLYywSMw_KdA9XuXc0ZnAQ4X-GDEDyfhIvUoCG4130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP149816.RAFaAvWLYywSMw_KdA9XuXc0ZnAQ4X-GDEDyfhIvUoCG4130_provenance.
• NP149818.RAPMBx2qDbK-W-LH_xf1myvGkhyQEONyG-FO6hNmL2q0w130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP149818.RAPMBx2qDbK-W-LH_xf1myvGkhyQEONyG-FO6hNmL2q0w130_provenance.
• NP185033.RAMrvc6EmS_Vq3PXp1ZMhkRRc5cXHgaPGz2MAFJ2LfotM130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185033.RAMrvc6EmS_Vq3PXp1ZMhkRRc5cXHgaPGz2MAFJ2LfotM130_provenance.
• NP185028.RA5emkjRcQD7jVWBMdrGsipacD0FTnaej9nmqGBicEqSY130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185028.RA5emkjRcQD7jVWBMdrGsipacD0FTnaej9nmqGBicEqSY130_provenance.
• NP185035.RA_pGi7voa-N-GnlXh-EUL1YHkGoBSZY21ZK2mR-h6SBc130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185035.RA_pGi7voa-N-GnlXh-EUL1YHkGoBSZY21ZK2mR-h6SBc130_provenance.
• NP185039.RA5i_QYqAQ5w0zQWOE78b07llrbaDQKWnlLjYX3thAAmc130_assertion description "[This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP185039.RA5i_QYqAQ5w0zQWOE78b07llrbaDQKWnlLjYX3thAAmc130_provenance.